Complement inhibitor, and preparation method therefor and use thereof
By introducing cysteine residues and binding to human serum albumin, fatty acid modification technology is used to prolong the half-life of OmCI protein, solving the problem of drug delivery frequency caused by the short half-life of OmCI protein, achieving a longer-lasting therapeutic effect, suitable for A variety of immune and inflammatory diseases.
Patent Information
- Application Number
- PCT/CN2024/093492
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-28
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-21
AI Technical Summary
The existing OmCI protein has a short in vivo half-life that requires daily intravenous administration, which affects patient compliance, and the prior art has failed to effectively prolong its half-life.
By introducing cysteine residue mutants and binding to human serum albumin, fatty acid modification techniques are used to prolong the in vivo half-life of OmCI protein to form a modified protein or pharmaceutical composition for the treatment of autoimmune diseases and inflammation.
It significantly prolongs the in vivo half-life of OmCI protein and provides a longer-lasting treatment plan. It is suitable for a variety of diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic ureemia, etc., improving patient compliance and treatment effect.
Smart Images

Figure PCTCN2024093492-FTAPPB-I100001 
Figure PCTCN2024093492-FTAPPB-I100002 
Figure PCTCN2024093492-FTAPPB-I100003
Abstract
Description
Complement inhibitors and their preparation and use Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to fatty acid side chain-modified OmCI mutants, as well as methods for preparing these mutants and their use in treating diseases. Background Art
[0002] Complement is a group of globulins that are present in the blood, tissue fluid, and cell membranes of humans and animals and have enzymatic activity after activation. Complement is a complex protein network composed of more than 50 proteins, and is therefore also called the complement system (Ricklin D, Lambris JD. Complement therapeutics. Semin Immunol. 2016; 28(3): 205-207). The components were originally named according to the order of discovery, C1-C4. This order was later corrected by the WHO in 1968, and named according to the activation order of C1-C9 (Kaufmann SH. Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol. 2008; 9(7): 705-712.). Complement, as an important component of innate immunity, mainly exerts its immunological function by regulating antigens to stimulate phagocytes to remove foreign matter and damaged substances, attracting macrophages and neutrophils to cause inflammation, and activating cell-killing membrane attack complexes.
[0003] Complement triggers immune function through a series of cascade reactions, including proteolysis, to amplify signals. Currently, there are three known complement activation pathways: a) the classical pathway, which requires an antigen-antibody complex to initiate C1 activation through a specific immune response; b) the alternative pathway, which requires no pathogen identification and relies solely on spontaneous C3 hydrolysis or activation to initiate activation; and c) the lectin pathway, in which lectins in the blood can specifically recognize and bind to mannose on the surface of pathogenic microorganisms. This pathway can be activated in the absence of antibodies through nonspecific immune responses such as C3 hydrolysis or antigens. The three complement activation pathways are shown in Figure 1.
[0004] The three pathways are activated by different initiation factors, all centered around the formation of C3 and C5 convertases. By cleaving C3 and C5 to produce corresponding bioactive fragments, they further amplify the complement response. In the downstream terminal pathway of the activation process, C5 is cleaved into C5a and C5b (Rawal N, Pangburn MK. Structure / function of C5 convertases of complement. Int Immunopharmacol. 2001; 1(3): 415-422). C5a is an anaphylatoxin and an important chemotactic protein that plays a key role in recruiting inflammatory cells. C5b recruits the membrane attack complex (MAC), composed of C6, C7, C8, and C9. MAC, as the end product of the complement cascade reaction, has the function of dissolving cell membranes. It can bind to the cell membrane of pathogens to form a hole, namely a transmembrane channel, causing the penetration of target cells, thereby killing or destroying pathogen cells (Serna M, Giles JL, Morgan BP, Bubeck D. Structural basis of complement membrane attack complex formation. Nat Commun. 2016; 7: 10587).
[0005] The immunological function of complement activation has a positive impact on the body's self-protection and anti-infection response. However, impaired and dysregulated complement responses are considered important pathogenic factors in several autoimmune diseases and various inflammatory conditions, such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy, and age-related macular degeneration (AMD). Complement C5, a representative molecule of the membrane attack complex in the complement system, is a large 188kDa protein with a serum concentration of 75μg / ml. Targeting this protein can regulate complement signaling activated by all three different pathways.
[0006] A natural protein with a molecular weight of approximately 17 kDa was extracted from the salivary glands of the soft tick (Ornithodoros moubata). Studies have shown that this protein can specifically bind to complement C5, inhibiting the downstream activation pathway of complement and preventing the formation of MAC. In addition to its targeted binding to complement C5, studies have also shown that the OmCI protein has the ability to inhibit the activity of leukotriene B4 (LTB4), providing additional anti-inflammatory function (Roversi P, Ryffel B, Togbe D, et al. Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury. J Biol Chem. 2013; 288(26): 18789-18802). Therefore, OmCI has a variety of clinical application potentials.
[0007] Rapid renal clearance of protein and peptide drugs is a common phenomenon in biopharmaceutical development. Although OmCI has a longer half-life than other small molecule biologics, with pOmCI having a circulating half-life of 30 hours, its clinical use still requires daily intravenous administration, which inevitably leads to poor patient compliance.
[0008] Among the several strategies currently used to extend the half-life of protein peptides in vivo, fatty acid modification technology is a long-term strategy based on endogenous albumin. Human serum albumin (HSA), as the most important protein in human plasma, can be used as a carrier to transport drugs, metabolites and fatty acids, with a half-life of approximately 19 days in the human body. Fatty acids reversibly bind to human serum albumin (HAS) in the body through non-covalent bonds, and participate in the circulation mediated by the neonatal receptor (FcRn), thereby achieving long-term drug effects. This strategy has also been widely used in a variety of peptide drugs. For example, Semaglutide, developed by Novo Nordisk, is based on human GLP-1 and is modified with fatty acid side chains to extend its injection frequency to once a week (Lau J, Bloch P, L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015; 58(18):7370-7380).
[0009] However, there is no method in the prior art to apply fatty acid modification strategy to OmCI protein to extend its half-life in vivo.
[0010] Summary of the Invention
[0011] The object of the present invention is to provide a method for extending the in vivo half-life of an OmCI protein, as well as an OmCI protein with an extended half-life and a pharmaceutical composition containing the same.
[0012] In a first aspect, the present invention provides a modified protein, comprising a protein portion and a modification portion, wherein a cysteine residue is introduced into the protein portion by mutation, and the modification portion is connected to the protein portion via the cysteine residue introduced into the protein portion, wherein the protein is OmCI or an active fragment thereof.
[0013] In a preferred embodiment, the mutation is a substitution or an insertion; preferably a substitution.
[0014] In a preferred embodiment, the OmCI has the amino acid sequence shown in SEQ ID NO: 1.
[0015] In a preferred embodiment, the OmCI has the amino acid sequence shown in SEQ ID NO: 1, and T90, K95, T97, E126 or S156 is mutated to a cysteine residue.
[0016] In a preferred embodiment, the amino acid sequence of OmCI is shown in any one of SEQ ID NOs: 4-8.
[0017] In a preferred embodiment, the amino acid sequence of OmCI is shown in any one of SEQ ID NOs: 4, 5, 7, and 8.
[0018] In a preferred embodiment, the modified moiety is capable of extending the in vivo half-life of the protein moiety.
[0019] In a preferred embodiment, the modified portion is capable of specifically or non-specifically binding to proteins in plasma.
[0020] In a preferred embodiment, the protein in the plasma has a long half-life; for example, the half-life of the protein in the plasma is 10 days or more, preferably 15 days or more, more preferably 19 days or more.
[0021] In a preferred embodiment, the protein in the plasma is human serum albumin.
[0022] In a preferred embodiment, the modifying moiety is an albumin binder.
[0023] In a preferred embodiment, the albumin binder is a fatty acid.
[0024] In a preferred embodiment, the structure of the albumin binder is shown below:
[0025] [R1-(X1) m -(X2) n -K] o -X3-(ε-R2);
[0026] Where K is lysine
[0027] R1 is substituted or unsubstituted C 1-20 acyl group;
[0028] m is an integer from 0 to 5;
[0029] n is an integer from 0 to 5;
[0030] o is an integer of 1-3 (preferably 1 or 2);
[0031] X1 and X2 are independently selected from the following group: alanine (Ala), D-alanine (D-Ala), β-alanine (β-Ala), 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), glutamic acid (Glu), D-glutamic acid (D-Glu), γ-glutamic acid (γ-Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met), tranexamic acid (Trx), 8-amino-3,6-dioxaoctanoic acid (AEEA), PEG;
[0032] X3 does not exist or is a connecting part as shown below:
[0033] (R3) o R4R5; wherein R3 is substituted or unsubstituted C 1-3 Acyl, R4 is C 5-8 Aryl or heteroaryl, R5 is a substituted or unsubstituted amino group;
[0034] R2 is selected from halogen-substituted C 1-6 acyl group.
[0035] In a preferred embodiment, R1 is selected from the group consisting of heptanoyl, methylheptanoyl, octanoyl, methyloctanoyl, nonanoyl, methylnonanoyl, decanoyl, methyldecanoyl, lauroyl, myristoyl, palmitoyl, octadecanoyl, 17-carboxyheptadecanoyl, 15-carboxypentadecanoyl, 13-carboxytridecanoyl, and 11-carboxoundecanoyl.
[0036] In a preferred embodiment, R1 is selected from the group consisting of lauroyl, myristoyl, palmitoyl, octadecanoyl, 17-carboxyheptadecanoyl, and 19-carboxynonadecanoyl.
[0037] In a preferred embodiment, m is an integer of 1-3.
[0038] In a preferred embodiment, n is an integer of 1-3.
[0039] In a preferred embodiment, X1 and X2 are independently selected from the following group: 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), D-alanine (D-Ala), β-alanine (β-Ala), aspartic acid (Asp), cysteine (Cys), glutamic acid (Glu), γ-glutamic acid (γ-Glu), glycine (Gly), serine (Ser), tyrosine (Tyr), 8-amino-3,6-dioxaoctanoic acid (AEEA), lysine (Lys).
[0040] In a preferred embodiment, X1 and X2 are independently selected from the group consisting of glutamic acid (Glu), γ-glutamic acid (γ-Glu), 8-amino-3,6-dioxaoctanoic acid (AEEA), and lysine (Lys).
[0041] In a preferred embodiment, the amino acid is preferably an L-amino acid.
[0042] In a preferred embodiment, R3 is formyl, R4 is phenyl, and R5 is amino.
[0043] In a preferred embodiment, R2 is selected from halogen-substituted C 1-3 acyl group.
[0044] In a preferred embodiment, R2 is selected from iodoacetyl or bromoacetyl; more preferably bromoacetyl.
[0045] In a preferred embodiment, the albumin binder is selected from the group consisting of:
[0046] In a preferred embodiment, it is characterized in that the modified protein is selected from the following group:
[0047] In a second aspect, the present invention provides an OmCI mutant having the amino acid sequence shown in SEQ ID NO: 1, wherein T90, K95, T97, E126 or S156 is mutated to a cysteine residue.
[0048] In a preferred embodiment, the amino acid sequence of OmCI is shown in any one of SEQ ID NOs: 4-8.
[0049] In a preferred embodiment, the amino acid sequence of OmCI is shown in any one of SEQ ID NOs: 4, 5, 7, and 8.
[0050] In a third aspect, the present invention provides a pharmaceutical composition comprising the modified protein according to the first aspect or the OmCI mutant according to the second aspect and a pharmaceutically acceptable excipient.
[0051] In a preferred embodiment, the pharmaceutical composition is used as a complement inhibitor.
[0052] In a preferred embodiment, the pharmaceutical composition is suitable for use in autoimmune diseases, inflammation, leukotriene or hydroxyeicosanoid-mediated diseases.
[0053] In a preferred embodiment, the pharmaceutical composition is suitable for paroxysmal nocturnal hemoglobinuria (PNH), atypical bullous pemphigoid, atopic keratoconjunctivitis, thrombotic microangiopathy (TMA), myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy, age-related macular degeneration (AMD), respiratory viral infections, autoimmune bullous diseases, and eye diseases (e.g., proliferative retinal diseases).
[0054] In a fourth aspect, the present invention provides use of the modified protein of the first aspect or the OmCI mutant of the second aspect in preparing a medicament.
[0055] In a preferred embodiment, the drug is a complement inhibitor.
[0056] In a preferred embodiment, the medicament is suitable for use in autoimmune diseases, inflammation, leukotriene or hydroxyeicosanoid mediated diseases.
[0057] In a preferred embodiment, the medicament is suitable for paroxysmal nocturnal hemoglobinuria (PNH), atypical bullous pemphigoid, atopic keratoconjunctivitis, thrombotic microangiopathy (TMA), myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy, age-related macular degeneration (AMD), respiratory viral infections, autoimmune bullous diseases, and eye diseases (e.g., proliferative retinal diseases).
[0058] In a fifth aspect, the present invention provides an albumin binder, the structure of which is shown in the following formula:
[0059] [R1-(X1) m -(X2) n -K] o -X3-(ε-R2);
[0060] Where K is lysine
[0061] R1 is substituted or unsubstituted C 1-20 acyl group;
[0062] m is an integer from 0 to 5;
[0063] n is an integer from 0 to 5;
[0064] o is an integer of 1-3 (preferably 1 or 2);
[0065] X1 and X2 are independently selected from the following group: alanine (Ala), D-alanine (D-Ala), β-alanine (β-Ala), 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), glutamic acid (Glu), D-glutamic acid (D-Glu), γ-glutamic acid (γ-Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met), tranexamic acid (Trx), 8-amino-3,6-dioxaoctanoic acid (AEEA), PEG;
[0066] X3 does not exist or is a connecting part as shown below:
[0067] (R3) o R4R5; wherein R3 is substituted or unsubstituted C 1-3 Acyl, R4 is C 5-8Aryl or heteroaryl, R5 is a substituted or unsubstituted amino group;
[0068] R2 is selected from halogen-substituted C 1-6 acyl group.
[0069] In a preferred embodiment, R1 is selected from the group consisting of heptanoyl, methylheptanoyl, octanoyl, methyloctanoyl, nonanoyl, methylnonanoyl, decanoyl, methyldecanoyl, lauroyl, myristoyl, palmitoyl, octadecanoyl, 17-carboxyheptadecanoyl, 15-carboxypentadecanoyl, 13-carboxytridecanoyl, and 11-carboxoundecanoyl.
[0070] In a preferred embodiment, R1 is selected from the group consisting of lauroyl, myristoyl, palmitoyl, octadecanoyl, 17-carboxyheptadecanoyl, and 19-carboxynonadecanoyl.
[0071] In a preferred embodiment, m is an integer of 1-3.
[0072] In a preferred embodiment, n is an integer of 1-3.
[0073] In a preferred embodiment, X1 and X2 are independently selected from the following group: 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), D-alanine (D-Ala), β-alanine (β-Ala), aspartic acid (Asp), cysteine (Cys), glutamic acid (Glu), γ-glutamic acid (γ-Glu), glycine (Gly), serine (Ser), tyrosine (Tyr), 8-amino-3,6-dioxaoctanoic acid (AEEA), lysine (Lys).
[0074] In a preferred embodiment, X1 and X2 are independently selected from the group consisting of glutamic acid (Glu), γ-glutamic acid (γ-Glu), 8-amino-3,6-dioxaoctanoic acid (AEEA), and lysine (Lys).
[0075] In a preferred embodiment, the amino acid is preferably an L-amino acid.
[0076] In a preferred embodiment, R3 is formyl, R4 is phenyl, and R5 is amino.
[0077] In a preferred embodiment, R2 is selected from halogen-substituted C 1-3 acyl group.
[0078] In a preferred embodiment, R2 is selected from iodoacetyl or bromoacetyl; more preferably bromoacetyl.
[0079] In a specific embodiment, the albumin binder is selected from the group consisting of:
[0080] In a sixth aspect, the present invention provides an isolated nucleic acid molecule encoding the OmCI mutant according to the second aspect.
[0081] In a seventh aspect, the present invention provides an expression vector comprising the isolated nucleic acid molecule of the sixth aspect.
[0082] In an eighth aspect, the present invention provides a host cell, wherein the host cell comprises the expression vector described in the seventh aspect or the nucleic acid molecule described in the sixth aspect is integrated into the genome of the host cell.
[0083] In a ninth aspect, the present invention provides use of the OmCI mutant described in the second aspect in preparing the modified protein described in the first aspect.
[0084] In a tenth aspect, the present invention provides a method of treatment, comprising the step of administering a therapeutically effective amount of the modified protein of the first aspect, the OmCI mutant of the second aspect, or the pharmaceutical composition of the third aspect to a subject in need thereof.
[0085] In preferred embodiments, the treatment method is applicable to autoimmune diseases, inflammatory diseases, leukotriene or hydroxyeicosanoid mediated diseases.
[0086] In a preferred embodiment, the treatment method is suitable for paroxysmal nocturnal hemoglobinuria (PNH), atypical bullous pemphigoid, atopic keratoconjunctivitis, thrombotic microangiopathy (TMA), myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy, age-related macular degeneration (AMD), respiratory viral infections, autoimmune blistering diseases, and eye diseases (e.g., proliferative retinal diseases).
[0087] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0088] Figure 1 is a schematic diagram of the three pathways of complement activation;
[0089] Figure 2 shows the SDS-PAGE images of the purified recombinant OmCI protein and its four mutants described in Examples 1 and 2; wherein, "1" is OmCIT90C; "2" is OmCIK95C; "3" is OmCIT97C; "4" is OmCIS156C; "5" is OmCI; "M" is Marker; "6" is OmCIT90C+DTT; "7" is OmCIK95C+DTT; "8" is OmCIT97C+DTT; "9" is OmCIS156C+DTT; and "10" is OmCI+DTT;
[0090] FIG3 shows the inhibition of PNH-like erythrocyte hemolysis in vitro by the recombinant OmCI protein and two modified derivatives described in Example 8;
[0091] FIG4 shows the pharmacokinetic parameters of the recombinant OmCI protein and two modified derivatives described in Example 11 in mice. DETAILED DESCRIPTION
[0092] After extensive and in-depth research, the inventors unexpectedly discovered a C5-targeting complement inhibitor, a modified derivative of an OmCI mutant. This OmCI mutant derivative exhibits excellent complement C5 inhibitory activity and a long in vivo half-life, providing a novel material foundation for the development of related drugs and possessing significant clinical potential. This led to the present invention.
[0093] definition
[0094] Unless otherwise indicated, the following terms used in this application have the following meanings. A particular term should not be construed as undefined or unclear unless specifically defined, but rather should be understood according to its ordinary meaning in the art. When a trade name appears in this document, it is intended to refer to the corresponding commercial product or its active ingredient.
[0095] The term "isolated nucleic acid molecule" refers to a nucleic acid molecule provided herein that: 1) is separated from at least about 50% of the protein, lipid, carbohydrate or other materials that coexist naturally with the nucleic acid when the nucleic acid is separated from the source cell, 2) is not connected to all or part of a polynucleotide that is naturally connected to the "isolated nucleic acid molecule," 3) is effectively connected to a polynucleotide that is not naturally connected to it, or 4) does not naturally exist as part of a larger polynucleotide sequence. Preferably, the isolated nucleic acid molecule is substantially free of any other contaminating nucleic acid molecules or other pollutants that may interfere with its use in polypeptide production or its treatment, diagnosis, prevention or research purposes that exist in its natural environment.
[0096] The term "vector" is used to refer to any molecule (eg, nucleic acid, plasmid, or virus) used to deliver coding information to a host cell.
[0097] The term "expression vector" refers to a vector suitable for host cell transformation and containing a nucleic acid sequence that directs and / or controls the expression of an inserted heterologous nucleic acid sequence. Expression includes, but is not limited to, processes such as transcription, translation, and RNA splicing (if introns are present).
[0098] The term "operably linked" is used herein to refer to an arrangement of flanking sequences in which the flanking sequences described herein are configured or assembled so as to perform their normal functions. Thus, a flanking sequence that is operably linked to a coding sequence may be capable of effecting replication, transcription, and / or translation of the coding sequence. For example, a coding sequence is operably linked to a promoter when the promoter is capable of directing transcription of the coding sequence. A flanking sequence need not be contiguous with a coding sequence, as long as it functions properly. Thus, for example, an intervening non-translated but transcribed sequence may be present between a promoter sequence and a coding sequence, and the promoter sequence may still be considered "operably linked" to the coding sequence.
[0099] The term "host cell" is used to refer to a cell that is transformed or capable of being transformed by a nucleic acid sequence (e.g., a nucleic acid provided herein) and is then capable of expressing a selected gene of interest. The term includes the progeny of a parent cell, whether or not the progeny are identical in morphology or genetic makeup to the original parent, as long as the selected gene is present.
[0100] "Substantially" means almost completely or completely, for example, one or more of the following is met: greater than 50%, 51% or greater, 75% or greater, 80% or greater, 90% or greater, and 95% or greater. As used herein, "sequence identity" is determined by aligning the sequence of a reference DNA with another DNA sequence so as to maximize the overlap between the two sequences and simultaneously minimize sequence gaps, wherein any protruding sequences between the two sequences are ignored. For any sequence identity described herein, at least 80% is preferred, 85% is more preferred, 90% is even more preferred, 95% sequence identity is even more preferred, and 96%, 97%, 98% and 99% sequence identity are most preferred.
[0101] The abbreviations for amino acid residues in proteins are as follows: Phe or F for phenylalanine; Leu or L for leucine; Ile or I for isoleucine; Met or M for methionine; Val or V for valine; Ser or S for serine; Pro or P for proline; Thr or T for threonine; Ala or A for alanine; Tyrosine is Tyr or Y; His or H for histidine; Gln or Q for glutamine; Asn or N for asparagine; Lys or Lys; Aspartic acid is Asp or D; Glu or E for glutamic acid; Cysteine is Cys or C; Tryptophan is Trp or W; Arginine is Arg or R; Glycine is Gly or G.
[0102] The term "optionally" or "optionally" means that the event or circumstance described subsequently may or may not occur, and the description includes both the occurrence of the event or circumstance and the non-occurrence of the event or circumstance. For example, an ethyl group is "optionally" substituted with a halogen, meaning that the ethyl group may be unsubstituted (CH2CH3), monosubstituted (such as CH2CH2F), polysubstituted (such as CHFCH2F, CH2CHF2, etc.), or fully substituted (CF2CF3). It will be understood by those skilled in the art that for any group containing one or more substituents, no substitution or substitution pattern that would be sterically impossible and / or incomposable to synthesize will be introduced.
[0103] As used herein, Cm-n means that there are mn carbon atoms in the moiety. For example, "C0-6 alkylene" means that the alkylene has 0-6 carbon atoms, and when the alkylene has 0 carbon atoms, the group is a bond.
[0104] Numeric ranges herein refer to each integer in the given range. For example, "C1-6" means that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms.
[0105] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition on each occurrence is independent. Thus, for example, if a group is substituted with two R's, each R has an independent alternative.
[0106] The term "substituted" refers to the replacement of any one or more hydrogen atoms on a particular atom by a substituent, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is an oxo (i.e., =O), it means that two hydrogen atoms are replaced. Oxo does not occur on aromatic groups.
[0107] The term "derivative" as a noun refers to a modified protein, i.e., a protein to which a moiety is bound in order to modify the properties of the protein; as a verb, the term refers to the process of binding a moiety to a protein to modify the properties of the protein.
[0108] OmCI and mutants thereof of the present invention
[0109] In the context of the present invention, the term "OmCI" as used herein refers to a recombinant tick-derived C5 complement inhibitor. This is a natural protein with a molecular weight of approximately 17 kDa extracted from the salivary glands of the soft tick (Ornithodoros moubata). Studies have shown that this protein can specifically bind to complement C5, inhibiting the downstream complement activation pathway and preventing the formation of MAC. CN1798841B discloses the recombinant sequence of this complement inhibitor. This inhibitor sequence consists of amino acids 1 to 168, of which the first 18 amino acids of the protein sequence form a signal sequence. Its mature form is a protein consisting of amino acids 19 to 168 as shown in CN1798841B. It is named "OmCI protein," "Coversin," or "Nomacopan." OmCI protein structure belongs to the lipocalin family. It has a compact folded structure, including a central eight-stranded antiparallel β barrel with three pairs of disulfide bonds at positions 24 and 146, 118 and 147, and 56 and 168, respectively (Roversi P, Lissina O, Johnson S, et al. The structure of OMCI, a novel lipocalin inhibitor of the complement system. J Mol Biol. 2007; 369(3): 784-793). In addition to its targeted binding to complement C5, studies have also shown that OmCI protein has the ability to inhibit the activity of leukotriene B4 (LTB4), providing additional anti-inflammatory function (Roversi P, Ryffel B, Togbe D, et al. Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury. J Biol Chem. 2013; 288(26): 18789-18802).
[0110] OmCI has a variety of clinical application potentials. For example, CN102066412A discloses its ability to bind to LTB4 eicosanoids and its use in treating diseases mediated by leukotrienes or hydroxyeicosanoids; CN101340926A discloses its effect in treating myasthenia gravis; CN102762223B discloses its effect in preventing respiratory viral infections and inflammation; CN106659767B discloses that it can treat or prevent subjects with C5 polymorphisms and complement-mediated disorders; CN110896606A discloses that it can be used as an effective method for treating and preventing autoimmune bullous disease (AIBD); CN110831617A discloses that it can be used to treat eye diseases; and CN114072206A discloses that it can treat or prevent proliferative retinal diseases.
[0111] The term mutant as used herein has the meaning conventionally understood by those skilled in the art. In a specific embodiment, a mutant is understood to be a compound obtained by the following steps: replacing one or more amino acid residues in the OmCI sequence with another natural or non-natural amino acid; and / or adding one or more natural or non-natural amino acids to the OmCI sequence; and / or deleting one or more amino acid residues from the OmCI sequence, wherein any of these steps may optionally be followed by further derivatization of one or more amino acid residues. Specifically, when an amino acid residue is substituted by another amino acid residue from the same group (i.e., by another amino acid residue with similar properties), such substitution is conservative. Amino acids can be appropriately divided into the following groups based on their properties: basic amino acids (e.g., arginine, lysine, histidine), acidic amino acids (e.g., glutamic acid and aspartic acid), polar amino acids (e.g., glutamine, cysteine, and asparagine), hydrophobic amino acids (e.g., leucine, isoleucine, proline, methionine, and valine), aromatic amino acids (e.g., phenylalanine, tryptophan, tyrosine), and small amino acids (e.g., glycine, alanine, serine, and threonine). Typically the OmCI mutant is at least 80%, eg, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to native OmCI derived from ticks.
[0112] As used herein, the term "OmCI fusion protein" refers to the fusion of one or more amino acid residues (eg, a heterologous protein or peptide) to the N-terminus or C-terminus of any of the OmCI mutants described herein. Heterologous peptides and polypeptides include, but are not limited to, epitopes for detecting and / or isolating OmCI protein mutants: transmembrane receptor proteins or portions thereof, such as extracellular domains or transmembrane and intracellular domains; ligands or portions thereof that bind to transmembrane receptor proteins; enzymes or catalytically active portions thereof; polypeptides or peptides that promote oligomerization, such as leucine zipper domains; polypeptides or peptides that improve stability, such as immunoglobulin constant regions (e.g., domains); half-life extending sequences comprising a combination of two or more (e.g., 2, 5, 10, 15, 20, 25, etc.) naturally occurring or non-naturally occurring, charged and / or uncharged amino acids (e.g., serine, glycine, glutamic acid, or aspartic acid) designed to form fusion partners for predominantly hydrophilic or predominantly hydrophobic mutants; functional or non-functional natural antibodies, or heavy or light chains thereof; and polypeptides having, for example, therapeutic activity other than that of the OmCI mutants of the present invention. OmCI fusion proteins can be prepared by fusing heterologous sequences to the N-terminus or C-terminus of an OmCI polypeptide mutant. Heterologous sequence as herein described can be an amino acid sequence or a polymer containing non-amino acids.Heterologous sequence can be directly fused with the OmCI mutant or fused by a joint or adapter molecule.Joint or adapter molecule can be one or more amino acid residues (or amino acid polymers), such as 1,2,3,4,5,6,7,8 or 9 residues (or amino acid polymers), preferably 10-50 amino acid residues (or amino acid polymers), such as 10,11,12,13,14,15,16,17,18,19,20,25,30,35,40,45 or 50 residues (or amino acid polymers), more preferably 15-35 amino acid residues (or amino acid polymers).Joint or adapter molecule can also be designed to have a cleavage site for DNA restriction endonuclease or protease for separating the fusion part.
[0113] As used herein, the terms "analogs" or "derivatives" before and after OmCI, i.e., OmCI analogs or OmCI derivatives, refer to proteins derived or derivable from natural OmCI, in particular from or from SEQ ID NO: 1, i.e., by modification of its amino acid sequence. Such modifications, amendments, or changes may include substitutions, deletions, and / or additions of one or more amino acids. For example, amino acids may be added and / or deleted at the C-terminus, N-terminus, or within the amino acid sequence. Preferably, amino acids are added and / or deleted at the C-terminus and / or N-terminus, more preferably at the N-terminus. An amino acid sequence having amino acids deleted from the C-terminus or N-terminus may also be referred to as a truncated sequence, as is known in the art. Similarly, amino acids added within the sequence may be referred to as insertions.
[0114] Rapid renal clearance of protein and peptide drugs is a common phenomenon in biopharmaceutical development. OmCI has a circulatory half-life of 30 hours, and daily dosing is clinically required, which inevitably affects patient compliance. In the present invention, the inventors modified OmCI with an albumin binder to extend its half-life. As used herein, albumin binder or albumin binding fragment has the same meaning. The meanings of both are not restrictive, but rather descriptive, as they reflect the overall goal or purpose of being linked to OmCI, that is, the resulting derivative (or analog) can bind to human serum albumin, and the purpose of the binding is to provide or at least contribute to the long-lasting effect of the analog of the present invention. If necessary, this term can also be replaced by other general chemical terms such as compound.
[0115] In the formula of the present invention, the albumin binder is a fatty acid. In a specific embodiment, the structure of the albumin binder is shown below:
[0116] [R1-(X1) m -(X2) n -K] o -X3-(ε-R2);
[0117] wherein K, R1, m, n, o, X1, X2 and X3 are as defined above.
[0118] In a specific embodiment, OmCI and its mutants are prepared as follows:
[0119] Methods for preparing recombinant OmCI and OmCI mutants are provided in one or more examples herein. OmCI and its mutants can be expressed in bacteria, such as Escherichia coli (E. coli), mammals, yeast, such as Pichia pastoris (P. pastoris), and plant expression systems. Expression can be performed exogenously (when the host cell naturally contains the desired genetic code) or endogenously. In some embodiments, OmCI and its mutants are expressed in E. coli.
[0120] Although recombinant-based methods for preparing proteins can vary, recombinant methods typically involve constructing a nucleic acid encoding the desired polypeptide or fragment, cloning the nucleic acid into an expression vector, transforming a host cell, and expressing the nucleic acid to produce the desired polypeptide or fragment. Methods for producing and expressing recombinant polypeptides in vitro and in prokaryotic host cells are known to those of ordinary skill in the art.
[0121] In one or more embodiments of the present invention, to obtain an OmCI analog of the correct sequence, a nucleotide sequence encoding an acid-sensitive tag can be inserted or added to the encoded sequence in frame, thereby producing a fusion protein comprising a desired polypeptide and a polypeptide containing an acid-sensitive tag.
[0122] In some embodiments, a genetic engineering method is provided for artificially synthesizing and expressing a fusion protein (precursor protein) comprising a desired polypeptide and a tag polypeptide. The recombinant gene sequence is inserted into an expression vector, and host cells are transformed. OmCI and its mutants are prepared through fermentation, high-pressure cell disruption, enzymatic digestion, and purification. The purity of OmCI and its mutants can be determined by any of a variety of known analytical methods, including gel electrophoresis and high-performance liquid chromatography, and their molecular weight can be determined by mass spectrometry.
[0123] In the present invention, OmCI cysteine mutants were prepared as follows:
[0124] One or more embodiments herein provide rationally designed OmCI mutants, particularly mutants in which certain amino acids of OmCI are mutated to cysteines. These mutants include five OmCI cysteine mutants, T90 (SEQ NO: 4), K95 (SEQ NO: 5), T97 (SEQ NO: 6), E126 (SEQ NO: 7), and S158C (SEQ NO: 8), obtained by mutating T90, K95, T97, E126, and S156, based on the sequence of SEQ NO: 1. Four OmCI cysteine mutants, including T90C (SEQ NO: 4), K95C (SEQ NO: 5), T97C (SEQ NO: 7), and S158C (SEQ NO: 8), were successfully prepared and their activities were determined using a classical pathway hemolytic assay. As is well known to those skilled in the art, compounds linked by disulfide bonds, including but not limited to OmCI-Cys, OmCI-reduced glutathione, OmCI-cysteamine, and the like, obtained by reacting with free Cys in the OmCI mutant, are also included in the OmCI mutant.
[0125] In the present invention, the albumin binder of the present invention is prepared as follows:
[0126] In some embodiments, it is mentioned that solid-phase synthesis of the albumin-binding fragment can be performed according to conventional solid-phase synthesis methods. The albumin-binding fragment can be purified by various known methods, and the purity and molecular weight of the albumin-binding fragment can be verified by high-performance liquid chromatography and mass spectrometry analysis.
[0127] The derivatives generally comprise an albumin binding fragment, the tag being non-toxic, non-naturally occurring and biocompatible, and typically the albumin binding fragment has a binding affinity for human serum albumin of less than about 10 μM or even less than about 1 μM.
[0128] In the present invention, the OmCI mutant modified derivatives can be prepared as follows:
[0129] In one or more embodiments herein, methods for preparing OmCI modified derivatives are provided. The OmCI modified derivatives prepared as described herein can be purified by techniques known in the art, such as reversed-phase high-performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like. The actual conditions used to purify a particular protein will depend in part on factors such as net charge, hydrophobicity, and hydrophilicity, and will be apparent to those skilled in the art. Ion exchange chromatography can be used to separate the modified derivatives, substantially as described in the Examples. The purity of the modified derivatives can be determined by any of a variety of known analytical methods, including gel electrophoresis, reversed-phase high-performance liquid chromatography, and the like, and molecular weight verification by mass spectrometry.
[0130] OmCI mutant derivatives with albumin binder modifications can be prepared as follows:
[0131] In one or more examples herein, the albumin binding fragment is reacted with the free cysteine on the OmCI mutant by halogenation reaction, ie, the fatty acid modified OmCI mutant is obtained to obtain an OmCI derivative.
[0132] In the context of the present invention, the term "pharmaceutically acceptable salt" means a salt that is harmless to patients. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium salts, and alkylated ammonium salts. Acid addition salts include salts of inorganic acids and organic acids. Representative examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, sulfuric acid, nitric acid, and the like. Representative examples of suitable organic acids include formic acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, propionic acid, benzoic acid, cinnamic acid, citric acid, fumaric acid, glycolic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, oxalic acid, picric acid, pyruvic acid, salicylic acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, tartaric acid, ascorbic acid, pamoic acid, bismethylene salicylic acid, ethanedisulfonic acid, gluconic acid, citric acid, aspartic acid, stearic acid, palmitic acid, EDTA, glycolic acid, p-aminobenzoic acid, glutamic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like. In addition, metal salts include lithium salts, sodium salts, potassium salts, magnesium salts, etc. Ammonium salts and alkylated ammonium salts include ammonium salts, methylammonium salts, dimethylammonium salts, trimethylammonium salts, ethylammonium salts, hydroxyethylammonium salts, diethylammonium salts, butylammonium salts, tetramethylammonium salts, etc.
[0133] The present application also includes isotopically labeled compounds of the present application that are identical to those described herein, but in which one or more atoms are replaced by atoms having an atomic mass or mass number different from that usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present application include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2H, 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 31P, 32P, 35S, 18F, 123I, 125I, and 36Cl, respectively.
[0134] Certain isotopically labeled compounds of the present invention (e.g., those labeled with 3H and 14C) can be used in compound and / or substrate tissue distribution analysis. Tritiation (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. In addition, substitution with heavier isotopes, such as deuterium (i.e., 2H), can provide certain therapeutic advantages (e.g., increased in vivo half-life or reduced dosage requirements) resulting from higher metabolic stability, and therefore may be preferred in some cases. Positron emitting isotopes, such as 15O, 13N, 11C, and 18F can be used in positron emission tomography (PET) studies to determine substrate occupancy. Isotopically labeled compounds of the present invention can generally be prepared by replacing an isotopically labeled reagent with an isotopically labeled reagent by the following procedures similar to those disclosed in the schemes and / or embodiments below.
[0135] Therapeutic Uses of OmCI Analogs: OmCI analogs can be used to treat, diagnose, ameliorate, or prevent a variety of diseases, disorders, or conditions, including but not limited to immunotherapy, including paroxysmal nocturnal hemoglobinuria (PNH), atypical bullous pemphigoid, atopic keratoconjunctivitis, thrombotic microangiopathy (TMA), myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy, age-related macular degeneration (AMD), and other diseases.
[0136] In use, the OmCI analogs described herein can be administered to a patient in need thereof in a therapeutically effective dose to treat conditions or illnesses such as PNH or aHUS. Administration can be as described herein, for example, by intravenous, subcutaneous, intraperitoneal, intramuscular injection, or orally in the form of a tablet or liquid formulation. In most cases, the desired dose can be determined by clinical staff as described herein and can represent a therapeutically effective dose of the OmCI protein analog. It will be apparent to those skilled in the art that a therapeutically effective dose of an OmCI analog will depend, among other things, on the dosing regimen, the unit dose of the substance administered (whether or not the nucleic acid molecule or polypeptide is administered in combination with other therapeutic agents), the immune status, and the health status of the recipient. As used herein, the term "therapeutically effective dose" means the amount of an OmCI analog that is sought by a researcher or other clinician to elicit a biological or pharmacological response in a tissue system, animal, or human, including alleviation of the symptoms of the disease or condition to be treated.
[0137] Advantages of the present invention:
[0138] 1. The present invention provides a novel modified protein;
[0139] 2. The modified protein of the present invention retains its original activity and its half-life in vivo is significantly improved;
[0140] 3. The modified protein of the present invention has a simple preparation process and can be easily obtained through biotechnology, chemical synthesis technology and other technical means; and
[0141] 4. The modified protein of the present invention lays a new material foundation for the development of therapeutic drugs for various diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical bullous pemphigoid, atopic keratoconjunctivitis, thrombotic microangiopathy (TMA), myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy, and age-related macular degeneration (AMD).
[0142] The following specific examples further illustrate the present invention. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally performed under conventional conditions, such as those described in (Sambrook and Russell et al., Molecular Cloning: A Laboratory Manual (Molecular Cloning-A Laboratory Manual) (3rd edition) (2001) CSHL Press), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight. The experimental materials and reagents used in the following examples can be obtained from commercial sources unless otherwise stated.
[0143] Example
[0144] Abbreviations SDS: sodium dodecyl sulfate DTT: dithiothreitol TFA: trifluoroacetic acid TCEP: tris(2-carboxyethyl)phosphine AEEA: 2-(2-(2-aminoethoxy)ethoxy)acetic acid RP-HPLC: reversed-phase high performance liquid chromatography Tris-HCl: tris(hydroxymethyl)aminomethane hydrochloride; Alloc: allyloxycarbonyl; Fmoc: 9-fluorenylmethoxycarbonyl; DIEA: N,N-diisopropylethylamine; DCM: dichloromethane; DIC: N,N'-diisopropylcarbodiimide; HOBt: 1-hydroxybenzotriazole; DMF: N,N-dimethylformamide; PIP: piperidine; IPTG: isopropyl-β-D-thiogalactoside; TCEP: tris(2-carboxyethyl)phosphine; Tris: tris(hydroxymethyl)aminomethane; GABA: γ-aminobutyric acid; Fmoc-Lys(Alloc)-OH: Nα-(9-Fluorenylmethoxycarbonyl)-Nε-allyloxycarbonyl-L-lysine; Fmoc-AEEA-OH: [2-[2-(9-Fluorenylmethoxycarbonyl-amino)ethoxy]ethoxy]acetic acid; Fmoc-Glu-OtBu: N-Fluorenylmethoxycarbonyl-L-glutamic acid-α-tert-butyl ester; PBS: potassium dihydrogen phosphate (KH2PO4): 0.24 g / L, disodium hydrogen phosphate (Na2HPO4): 1.44 g / L, sodium chloride (NaCl): 8 g / L, potassium chloride (KCl): 0.2 g / L, pH 7.4.
[0145] General Detection and Characterization Methods
[0146] RP-HPLC
[0147] LC-MS method
[0148] SDS-PAGE analysis
[0149] 15% pre-cast gels were used. Samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Samples were prepared, loaded onto the gel and electrophoresis was performed as described by the manufacturer.
[0150] Protein quantification
[0151] The protein concentration was determined by using a BCA kit.
[0152] Data analysis was performed using GraphPad Prims software version 8.01 (GraphPad Software Inc., San Diego, CA, USA).
[0153] Example 1: Preparation of recombinant OmCI protein
[0154] (1) OmCI is naturally derived from the salivary glands of ticks, and its sequence is available on Uniport (ID: Q5YD09) as SEQ ID NO: 1. The native OmCI protein consists of amino acids 1 to 168, of which the first 18 amino acids form a signal sequence that is not essential for C5-binding activity or LTB4-binding activity. The mature form of the protein consists of amino acids 19 to 168, and therefore, the amino acid sequence of the mature protein can be used for the efficiency of recombinant protein production.
[0155] Considering the three pairs of disulfide bonds in the protein structure, an extracellular expression system for the recombinant OmCI protein was established in the form of a fusion protein. An expression cassette containing an N-terminal enterokinase recognition site (GSGDEGD) and a periplasmic binding protein (ArgT; UniProt ID P09551) for OmCI expression was constructed and inserted into the pET30 plasmid. The cassette was then transformed into competent E. coli BL21 (DE3) bacteria, and an engineered strain for expressing the ArgT-GSGDEGD-OmCI (SEQ ID NO: 2) fusion protein was obtained through screening. After high-density fermentation, the engineered bacteria expressed the ArgT-GSGDEGD-OmCI fusion protein in a soluble form outside the cells.
[0156] (2) Soluble fusion protein ArgT-GSGDEGD-OmCI (SEQ ID NO: 2) can be purified after enzyme digestion to obtain soluble target OmCI recombinant protein. First, the pH of the fermentation broth was adjusted to 4.0, and after centrifugation, it was clarified. Then, the pH was adjusted to 8.0. Recombinant bovine enterokinase light chain (which can specifically cut the GSGDEGD site) was added at 37°C for enzyme digestion reaction. The pH of the treated enzyme digestion solution was adjusted to 6.5. Anion exchange chromatography (HiTrap Q HP (5 ml, purchased from Cytiva) was used to maintain the chromatography pH at 6.5. The elution was performed with a linear salt gradient of 0-500 mM NaCl. After SDS-PAGE analysis and RP-HPLC analysis, the soluble target OmCI protein with high purity was obtained. Finally, the OmCI protein was concentrated by ultrafiltration using a MWCO 3kDa filter membrane and replaced with PBS.
[0157] After LC-MS analysis, the measured molecular weight of OmCI prepared according to the above method was 16779.85 Da, which was consistent with the theoretical molecular weight (16779.59 Da).
[0158] Example 2: Preparation of OmCI mutant protein
[0159] (1) Design of OmCI mutant proteins
[0160] Based on the crystal structure of OmCI and its related receptor complexes, bioinformatics software was used to design single Cys mutation sites. The purpose was to make the free Cys obtained by mutation available for chemical modification, including the albumin binding fragment. First, the crystal structure of OmCI (PDB ID: 2CM4) and the complex structures of OmCI with its receptor (complement C5) and receptor (LTB4) (OmCI-C5; PDB ID: 5HCC and OmCI-LTB4; PDB ID: 3ZUO) were downloaded from the Protein Data Bank database (https: / / www1.rcsb.org / ). Based on these crystal structures, the position of the cysteine mutation should not affect the function and structure of OmCI itself and should be easy to modify the subsequent albumin binding fragment. In other words, the following three points should be met: (1) conservative mutations should be selected to avoid affecting the binding of OmCI to its receptor, that is, amino acids involved in the interaction should not be mutated; (2) the formation of three disulfide bonds should not be affected; and (3) the position should be solvent accessible on the protein surface. Cysteine mutations were performed on T90 (SEQ ID NO: 4), K95 (SEQ ID NO: 5), T97 (SEQ ID NO: 6), E126 (SEQ ID NO: 7), and S156 (SEQ ID NO: 8) of OmCI. These OmCI cysteine mutants were engineered, fermented, and purified as described in Example 2. With the exception of the OmCIE126C mutant, which proved difficult to express and purify, all other mutants were successfully prepared.
[0161] (2) OmCIT90C, OmCIK95C, OmCIT97C, OmCIE126C, and OmCIS156C were expressed in the form of tag fusion proteins. Taking OmCIT90C as an example, an expression cassette containing an N-terminal 6-histidine (His6) tag and a ubiquitin-like modifier protein (SUMO) tag for the expression of OmCI mutants was constructed and inserted into the pET30 plasmid. It was then transformed into competent E. coli BL21 (DE3) bacteria, and an engineered strain for expressing the His6-SUMO-OmCIT90C (SEQ ID NO: 3) fusion protein was obtained by screening. The engineered bacteria were fermented at high density to express the His6-SUMO-OmCIT90C fusion protein in a soluble form in the periplasmic space.
[0162] (3) First, purify the soluble fusion protein His6-SUMO-OmCIT90C (SEQ ID NO: 3), obtain the soluble target OmCIS156C mutant protein by enzyme digestion, and then purify to obtain the soluble target OmCIT90C mutant protein with higher purity. Add 0.05% PEI to the bacterial resuspension and extract at 50°C for 2 hours to extract the soluble fusion protein expressed in the periplasm; during the entire separation and purification process, the resuspension buffer is supplemented with 10mM cysteine as a blocking agent to allow the mutant cysteine on the target protein to bind to the exogenous free cysteine to form the fusion protein His6-SUMO-OmCIT90C-Cys, thereby preventing aggregation between protein monomers. The pH of the extract was then adjusted to 6.0, clarified after centrifugation, and then adjusted to 7.4. The fusion protein was enriched by metal ion chelation chromatography (IMAC) HisTrap Ni excel (5 ml, purchased from Cytiva), and the fusion protein containing the His6 tag was eluted with 0.3 M imidazole. The eluted peak was collected and subjected to anion exchange chromatography (HiTrap Q HP (5 ml, purchased from Cytiva), maintaining the chromatography pH at 7.4, and eluted with a linear salt gradient of 0–500 mM NaCl. ULP1 enzyme (which can specifically cleave the SUMO tag) was added to the eluted peak and digested at 32°C. The tagged protein (His6-SUMO) was removed from the digested solution by metal ion chelation chromatography (IMAC). The effluent was collected, analyzed by SDS-PAGE and RP-HPLC, and then combined to obtain the target OmCIT90C (SEQ ID NO: 1) with high purity. The OmCIT90C mutant was primarily present as the target OmCIT90C-Cys mutant protein, in which the mutated cysteine was blocked, along with a free monomeric form (OmCIT90C) in which the cysteine was not blocked. The OmCIT90C mutant protein was then concentrated by ultrafiltration using a MWCO 3 kDa filter membrane and replaced with PBS.
[0163] After LC-MS analysis, the measured molecular weight of the monomer OmCIT90C without blocked cysteine prepared according to the above method was 16781.2 Da, which was consistent with the theoretical molecular weight (16781.63 Da). The measured molecular weight of the cysteine-blocked OmCIT90C-Cys mutant was 16900.80 Da, which was consistent with the theoretical molecular weight (16900.79 Da).
[0164] In the following examples, several other OmCI mutant proteins were expressed in a bacterial expression system such as E. coli BL21(DE3). Unless otherwise indicated, expression and purification were performed according to the methods described in this example. The results of LC-MS analysis are as follows:
[0165] Table 1. LC-MS analysis results of OmCI protein and its mutants
[0166] Example 3: Synthesis of albumin binding fragments
[0167] 3.1 CM03:HO2C-(CH2) 16 -Synthesis of CO-AEEA-γGlu-γGlu-Lys-CO-CH2-Br
[0168] Brominated fatty acid side chains were synthesized according to solid-phase chemistry: 1.00 g of 2-CTC resin was weighed and placed in a peptide synthesizer reactor. 10 ml of DCM was added and allowed to swell for 1 h. 2-3 times the amount of Fmoc-Lys(Alloc)-OH and 4-6 times the amount of DIEA were weighed and dissolved in 10 ml of DMF. The resin was then placed in the reactor and reacted at room temperature for 2 h. The first amino acid was coupled to the resin. The resin was then washed with DCM six times, and the substitution value (SD) of the resin was measured. 10 ml of a 20% PIP / DMF solution was then added and mixed for 10 min to remove the amino protecting group Fmoc. This process was repeated, and the resin was then washed with DCM six times. The second amino acid was coupled. 3 times the amount of Fmoc-Glu-otBu, HOBt, and DIC were weighed and dissolved in 10 ml of a DMF / DCM (1:1) mixed solvent. The reaction was allowed to react at room temperature. The reaction progress was monitored with ninhydrin. The reaction was complete when colorless. The resin was then washed with DCM six times. Then, the reaction can be continued according to the above coupling method, and the cycle is repeated until the coupling is completed.
[0169] Weigh tetrakis(triphenylphosphine)palladium (0.1 times the amount) and phenylsilane (10 times the amount) and dissolve them in 15ml of DCM before adding them to the reactor to react with the resin peptide for 25 minutes. This process must be carried out under light-proof and nitrogen protection conditions. After the reaction is completed, use DCM (15ml*6 times, 2 minutes each time), 0.02mol / LN,N-diethyldithiocarbamic acid / DMF solution (15ml*3 times, 2 minutes each time), DMF (15ml*6 times, 2 minutes each time) and take a small amount of resin for ninhydrin test. The resin particles turn purple-black, indicating that the deprotection is complete.
[0170] Add 2 equivalents of bromoacetyl bromide and 10 ml of DMF, react at room temperature for 1 hour, monitor the reaction progress with ninhydrin, and the reaction is complete when it turns colorless. Wash the resin with DCM 6 times, dry the resin peptide in vacuum and set aside.
[0171] The cleavage reagent was added at a ratio of TFA:TIS:H2O = 95:2.5:2.5 (V:V) per 1 g resin. The reaction was carried out at room temperature for 1 h. The resin was removed by filtration. The filtrate was rotary evaporated at 40°C to remove TFA as much as possible. The fatty acid side chains were precipitated with 7-10 times icy ether. The mixture was placed in a -20°C refrigerator for 20 min, centrifuged, and vacuum dried to obtain the fatty acid side chains.
[0172] Theoretical molecular weight: 966.96 Da; measured molecular weight: 967.43 Da.
[0173] In the following examples, the solid phase chemical synthesis of brominated fatty acid side chains and other albumin binding fragments was carried out according to the method described in this example unless otherwise stated.
[0174] 3.2 CM04:HO2C-(CH2) 14 -Synthesis of CO-AEEA-γGlu-γGlu-Lys-CO-CH2-Br
[0175] Procedure: Prepare as described in 3.1.
[0176] Theoretical molecular weight: 938.91 Da; measured molecular weight: 939.40 Da.
[0177] 3.3 CM05:HO2C-(CH2) 18 -Synthesis of CO-AEEA-γGlu-γGlu-Lys-CO-CH2-Br
[0178] Procedure: Prepare as described in 3.1.
[0179] Theoretical molecular weight: 995.02 Da; measured molecular weight: 995.55 Da.
[0180] 3.4 CM06:HO2C-(CH2) 20 -Synthesis of CO-AEEA-γGlu-γGlu-Lys-CO-CH2-Br
[0181] Procedure: Prepare as described in 3.1.
[0182] Theoretical molecular weight: 1023.07 Da; measured molecular weight: 1023.60 Da.
[0183] 3.5 CM07:HO2C-(CH2) 14 -Synthesis of CO-γGlu-AEEA-AEEA-Lys-CO-CH2-Br
[0184] Procedure: Prepare as described in 3.1.
[0185] Theoretical molecular weight: 954.95 Da; measured molecular weight: 955.44 Da.
[0186] 3.6 CM08:HO2C-(CH2) 16 -Synthesis of CO-γGlu-AEEA-AEEA-Lys-CO-CH2-Br
[0187] Procedure: Prepare as described in 3.1.
[0188] Theoretical molecular weight: 983.01 Da; measured molecular weight: 983.49 Da.
[0189] 3.7 CM09:CH3-(CH2) 16 -Synthesis of CO-γGlu-AEEA-AEEA-Lys-CO-CH2-Br
[0190] Procedure: Prepare as described in 3.1.
[0191] Theoretical molecular weight: 953.02 Da; measured molecular weight: 953.30 Da.
[0192] 3.8 CM10:HO2C-(CH2) 18 -Synthesis of CO-γGlu-AEEA-AEEA-Lys-CO-CH2-Br
[0193] Procedure: Prepare as described in 3.1.
[0194] Theoretical molecular weight: 1011.06 Da; measured molecular weight: 1011.51 Da.
[0195] 3.9 CM11:HO2C-(CH2) 14 Synthesis of -CO-γGlu-εLys-εLys-Lys-CO-CH2-Br
[0196] Procedure: Prepare as described in 3.1.
[0197] Theoretical molecular weight: 920.99 Da; measured molecular weight: 921.49 Da.
[0198] 3.10 CM12:HO2C-(CH2) 16 Synthesis of -CO-γGlu-εLys-εLys-Lys-CO-CH2-Br
[0199] Procedure: Prepare as described in 3.1.
[0200] Theoretical molecular weight: 949.04 Da; measured molecular weight: 949.53 Da.
[0201] 3.11 CM14:HO2C-(CH2) 18 Synthesis of -CO-γGlu-εLys-εLys-Lys-CO-CH2-Br
[0202] Procedure: Prepare as described in 3.1.
[0203] Theoretical molecular weight: 977.09 Da; measured molecular weight: 977.59 Da.
[0204] 3.12 CM15:[HO2C-(CH2) 16 -Synthesis of CO-γGlu-AEEA-AEEA-Lys-CO-]2-C6H3-NH-CO-CH2-Br
[0205] Procedure: Prepare as described in 3.1.
[0206] Theoretical molecular weight: 1988.00Da; measured molecular weight: 1989.68Da
[0207] Example 4: Preparation of OmCI mutant derivatives modified with albumin binding fragments
[0208] 4.1 OmCIT90C-CM03: OmCI-Cys 90 -[S-CH2CO-Lys-γGlu-γGlu-AEEA-CO-(CH2) 16 Preparation of [-CO2H]
[0209] The compound is an OmCI mutant derivative (OmCIT90C-CM03) obtained by modifying the OmCIT90C mutant of SEQ ID NO: 4 (Example 2) with the albumin binder (CM03) described in Example 3.1. The specific preparation process and identification are as follows.
[0210] Procedure: Prior to the modification reaction, the cysteine-blocked OmCIT90C-Cys mutant was ultrafiltered into PBS buffer (pH 7.4) to a final concentration of 1 mg / mL. 0.5 mM TCEP (tris(2-carboxyethyl)phosphine, dissolved in PBS buffer and adjusted to pH 7.4) was added and the reaction was allowed to proceed in a 37°C water bath for 2 h. The albumin binder described in Example 3.1 was dissolved in saturated ammonium bicarbonate solution. The dissolved albumin-binding fragment solution was added to the OmCI mutant at a molar ratio of 1:10, OmCI mutant:albumin-binding fragment, and the reaction was stirred overnight. Following the reaction, the albumin-binding-modified OmCI mutant derivative was purified using anion exchange chromatography on a 30Q column (purchased from Suzhou Saifen). The pH of the chromatography column was maintained at 7.4, and elution was performed using a linear salt gradient from 0–500 mM NaCl. The target peaks were combined after RP-HPLC analysis and SDS-PAGE analysis to obtain the OmCIT90C mutant of SEQ ID NO: 4 (Example 2) with higher purity, which was an OmCI mutant derivative modified with the albumin binding fragment (CM03) as described in Example 3.1.
[0211] Theoretical molecular weight: 17667.68 Da; measured molecular weight: 17667.12 Da.
[0212] 4.2 OmCIT90C-CM05: OmCI-Cys 90 -[S-CH2CO-Lys-γGlu-γGlu-AEEA-CO-(CH2) 18 Preparation of [-CO2H]
[0213] This compound is an OmCI mutant derivative obtained by modifying the OmCIT90C mutant of SEQ ID NO: 4 (Example 2) with the albumin binding fragment (CM05) described in Example 3.3. The preparation process and identification are as follows.
[0214] Procedure: Prepare as described in 4.1.
[0215] Theoretical molecular weight: 17695.68 Da; measured molecular weight: 17694.83 Da.
[0216] 4.3 OmCIT90C-CM06: OmCI-Cys 90 -[S-CH2CO-Lys-γGlu-γGlu-AEEA-CO-(CH2) 20 Preparation of [-CO2H]
[0217] The compound is an OmCI mutant derivative obtained by modifying the OmCIT90C mutant of SEQ ID NO: 4 (Example 2) with the albumin binding fragment (CM06) described in Example 3.4. The preparation process and identification are as follows.
[0218] Procedure: Prepare as described in 4.1.
[0219] Theoretical molecular weight: 17725.68 Da; measured molecular weight: 17724.12 Da.
[0220] 4.4 OmCIT90C-CM10:OmCI-Cys 90 -[S-CH2CO-Lys-AEEA-AEEA-γGlu-CO-(CH2) 18 Preparation of [-CO2H]
[0221] This compound is an OmCI mutant derivative obtained by modifying the OmCIT90C mutant of SEQ ID NO: 4 (Example 2) with an albumin binder (CM10) as described in Example 3.8. The preparation process and identification are as follows.
[0222] Procedure: Prepare as described in 4.1.
[0223] Theoretical molecular weight: 17711.78 Da; measured molecular weight: 17711.29 Da.
[0224] 4.5 OmCIT90C-CM14:OmCI-Cys 90 -[S-CH2-CO-Lys-εLys-εLys-γGlu-CO-(CH2) 18 Preparation of [-CO2H]
[0225] This compound is an OmCI mutant derivative obtained by modifying the OmCIT90C mutant of SEQ ID NO: 4 (Example 2) with an albumin binder (CM14) as described in Example 3.11. The preparation process and identification are as follows.
[0226] Procedure: Prepare as described in 4.1.
[0227] Theoretical molecular weight: 17677.81 Da; measured molecular weight: 17677.10 Da.
[0228] 4.6 OmCIT97C-CM03:OmCI-Cys 97 -[S-CH2CO-Lys-γGlu-γGlu-AEEA-CO-(CH2)16 Preparation of [-CO2H]
[0229] This compound is an OmCI mutant derivative obtained by modifying the OmCIT97C mutant of SEQ ID NO: 6 (Example 2) with an albumin binder (CM03) as described in Example 3.1. The preparation process and identification are as follows.
[0230] Procedure: Prepare as described in 4.1.
[0231] Theoretical molecular weight: 17667.68 Da; measured molecular weight: 17668.24 Da.
[0232] 4.7 OmCIT97C-CM05: OmCI-Cys 97 -[S-CH2CO-Lys-γGlu-γGlu-AEEA-CO-(CH2) 18 Preparation of [-CO2H]
[0233] This compound is an OmCI mutant derivative obtained by modifying the OmCIT97C mutant of SEQ ID NO: 6 (Example 2) with the albumin binding fragment (CM05) described in Example 3.3. The preparation process and identification are as follows.
[0234] Procedure: Prepare as described in 4.1.
[0235] Theoretical molecular weight: 17695.68 Da; measured molecular weight: 17695.25 Da.
[0236] 4.8 OmCIT97C-CM06: OmCI-Cys 97 -[S-CH2CO-Lys-γGlu-γGlu-AEEA-CO-(CH2) 20 Preparation of [-CO2H]
[0237] This compound is an OmCI mutant derivative obtained by modifying the OmCIT97C mutant of SEQ ID NO: 6 (Example 2) with the albumin binding fragment (CM06) described in Example 3.4. The preparation process and identification are as follows.
[0238] Procedure: Prepare as described in 4.1.
[0239] Theoretical molecular weight: 17725.68 Da; measured molecular weight: 17724.36 Da.
[0240] 4.9 OmCIT97C-CM09:OmCI-Cys 97-[S-CH2CO-Lys-AEEA-AEEA-γGlu-CO-(CH2) 16 Preparation of [-CH3]
[0241] This compound is an OmCI mutant derivative obtained by modifying the OmCIT97C mutant of SEQ ID NO: 6 (Example 2) with an albumin binder (CM09) as described in Example 3.7. The preparation process and identification are as follows.
[0242] Procedure: Prepare as described in 4.1.
[0243] Theoretical molecular weight: 17653.74 Da; measured molecular weight: 17651.22 Da.
[0244] 4.10 OmCIT97C-CM10:OmCI-Cys 97 -[S-CH2CO-Lys-AEEA-AEEA-γGlu-CO-(CH2) 18 Preparation of [-CO2H]
[0245] This compound is an OmCI mutant derivative obtained by modifying the OmCIT97C mutant of SEQ ID NO: 6 (Example 2) with an albumin binder (CM10) as described in Example 3.8. The preparation process and identification are as follows.
[0246] Procedure: Prepare as described in 4.1.
[0247] Theoretical molecular weight: 17711.78Da; measured molecular weight: 17711.26Da.
[0248] 4.11 OmCIT97C-CM14:OmCI-Cys 97 -[S-CH2-CO-Lys-εLys-εLys-γGlu-CO-(CH2) 18 Preparation of [-CO2H]
[0249] This compound is an OmCI mutant derivative obtained by modifying the OmCIT97C mutant of SEQ ID NO: 6 (Example 2) with an albumin binder (CM14) as described in Example 3.11. The preparation process and identification are as follows.
[0250] Procedure: Prepare as described in 4.1.
[0251] Theoretical molecular weight: 17677.81 Da; measured molecular weight: 17677.28 Da.
[0252] 4.12 OmCIS156C-CM03:OmCI-Cys 156 -[S-CH2CO-Lys-γGlu-γGlu-AEEA-CO-(CH2) 16 Preparation of [-CO2H]
[0253] The compound is an OmCI mutant derivative obtained by modifying the OmCIS156C mutant of SEQ ID NO: 8 (Example 2) with an albumin binder (CM03) as described in Example 3.1. The preparation process and identification are as follows.
[0254] Procedure: Prepare as described in 4.1.
[0255] Theoretical molecular weight: 17681.70Da; measured molecular weight: 17681.64Da.
[0256] 4.13 OmCIS156C-CM05: OmCI-Cys 156 -[S-CH2CO-Lys-γGlu-γGlu-AEEA-CO-(CH2) 18 Preparation of [-CO2H]
[0257] The compound is an OmCI mutant derivative obtained by modifying the OmCIS156C mutant of SEQ ID NO: 8 (Example 2) with the albumin binding fragment (CM05) described in Example 3.3. The preparation process and identification are as follows.
[0258] Procedure: Prepare as described in 4.1.
[0259] Theoretical molecular weight: 17709.70 Da; measured molecular weight: 17709.74 Da.
[0260] 4.14 OmCIS156C-CM06: OmCI-Cys 156 -[S-CH2CO-Lys-γGlu-γGlu-AEEA-CO-(CH2) 20 Preparation of [-CO2H]
[0261] The compound is an OmCI mutant derivative obtained by modifying the OmCIS156C mutant of SEQ ID NO: 8 (Example 2) with the albumin binding fragment (CM06) described in Example 3.4. The preparation process and identification are as follows.
[0262] Procedure: Prepare as described in 4.1.
[0263] Theoretical molecular weight: 17737.70 Da; measured molecular weight: 17737.80 Da.
[0264] 4.15 OmCIS156C-CM07:OmCI-Cys 156 -[S-CH2-CO-Lys-AEEA-AEEA-γGlu-CO-(CH2) 14 Preparation of [-CO2H]
[0265] The compound is an OmCI mutant derivative obtained by modifying the OmCIS156C mutant of SEQ ID NO: 8 (Example 2) with the albumin binding fragment (CM07) described in Example 3.5. The preparation process and identification are as follows.
[0266] Procedure: Prepare as described in 4.1.
[0267] Theoretical molecular weight: 17669.69 Da; measured molecular weight: 17669.28 Da.
[0268] 4.16 OmCIS156C-CM08:OmCI-Cys 156 -[S-CH2-CO-Lys-AEEA-AEEA-γGlu-CO-(CH2) 16 Preparation of [-CO2H]
[0269] This compound is an OmCI mutant derivative obtained by modifying the OmCIS156C mutant of SEQ ID NO: 8 (Example 2) with an albumin binder (CM08) as described in Example 3.6. The preparation process and identification are as follows.
[0270] Procedure: Prepare as described in 4.1.
[0271] Theoretical molecular weight: 17697.75 Da; measured molecular weight: 17697.34 Da.
[0272] 4.17 OmCIS156C-CM09:OmCI-Cys 156 -[S-CH2-CO-Lys-AEEA-AEEA-γGlu-CO-(CH2) 16 Preparation of [-CH3]
[0273] This compound is an OmCI mutant derivative obtained by modifying the OmCIS156C mutant of SEQ ID NO: 8 (Example 2) with an albumin binder (CM09) as described in Example 3.7. The preparation process and identification are as follows.
[0274] Procedure: Prepare as described in 4.1.
[0275] Theoretical molecular weight: 17667.76 Da; measured molecular weight: 17667.39 Da.
[0276] 4.18 OmCIS156C-CM10:OmCI-Cys 156 -[S-CH2-CO-Lys-AEEA-AEEA-γGlu-CO-(CH2) 18 Preparation of [-CO2H]
[0277] This compound is an OmCI mutant derivative obtained by modifying the OmCIS156C mutant of SEQ ID NO: 8 (Example 2) with an albumin binder (CM10) as described in Example 3.8. The preparation process and identification are as follows.
[0278] Procedure: Prepare as described in 4.1.
[0279] Theoretical molecular weight: 17725.80 Da; measured molecular weight: 17725.24 Da.
[0280] 4.19 OmCIS156C-CM11:OmCI-Cys 156 -[S-CH2-CO-Lys-εLys-εLys-γGlu-CO-(CH2) 14 Preparation of [-CO2H]
[0281] This compound is an OmCI mutant derivative obtained by modifying the OmCIS156C mutant of SEQ ID NO: 8 (Example 2) with an albumin binder (CM11) as described in Example 3.9. The preparation process and identification are as follows.
[0282] Procedure: Prepare as described in 4.1.
[0283] Theoretical molecular weight: 17635.73 Da; measured molecular weight: 17636.43 Da.
[0284] 4.20 OmCIS156C-CM12:OmCI-Cys 156 -[S-CH2-CO-Lys-εLys-εLys-γGlu-CO-(CH2) 16 Preparation of [-CO2H]
[0285] This compound is an OmCI mutant derivative obtained by modifying the OmCIS156C mutant of SEQ ID NO: 8 (Example 2) with an albumin binder (CM12) as described in Example 3.10. The preparation process and identification are as follows.
[0286] Procedure: Prepare as described in 4.1.
[0287] Theoretical molecular weight: 17663.78 Da; measured molecular weight: 17662.74 Da.
[0288] 4.21 OmCIS156C-CM14:OmCI-Cys 156 -[S-CH2-CO-Lys-εLys-εLys-γGlu-CO-(CH2) 18 Preparation of [-CO2H]
[0289] This compound is an OmCI mutant derivative obtained by modifying the OmCIS156C mutant of SEQ ID NO: 8 (Example 2) with an albumin binder (CM14) as described in Example 3.11. The preparation process and identification are as follows.
[0290] Procedure: Prepare as described in 4.1.
[0291] Theoretical molecular weight: 17691.83 Da; measured molecular weight: 17691.31 Da.
[0292] 4.22 OmCIS156C-CM15:OmCI-Cys 156 -[S-CH2-CO-NH-C6H3-[-CO-Lys-AEEA-AEEA-γGlu-CO-(CH2) 16 Preparation of [-CO2H]2]
[0293] This compound is an OmCI mutant derivative obtained by modifying the OmCIS156C mutant of SEQ ID NO: 8 (Example 2) with an albumin binder (CM15) as described in Example 3.12. The preparation process and identification are as follows.
[0294] Procedure: Prepare as described in 4.1.
[0295] Theoretical molecular weight: 18702.74 Da; measured molecular weight: 18702.19 Da.
[0296] Table 2. LC-MS analysis results of OmCI modified derivatives
[0297] Example 5: Classical complement pathway hemolysis test (CH50)
[0298] For the classical pathway hemolysis inhibition assay (CH50), the assay was performed according to the method described in CN1798841B. 2 mL of fresh sterile sheep defibrinated blood (1:1 v / v) in Alsever's was washed once with 20 mL of GVBE (0.1% gelatin, 5 mM barbital, 145 mM NaCl, 10 mM EDTA; pH 7.4) buffer, centrifuged at 2500 × g for 10 min, and the supernatant discarded. The blood was then washed three times with 20 mL of GVB++ (0.1% gelatin, 5 mM barbital, 145 mM NaCl, 0.15 mM CaCl2, 0.5 mM MgCl2; pH 7.4) buffer. The pelleted red blood cells were diluted proportionally in GVB++ buffer to prepare 4 × 10 8 cell / mL of sheep erythrocytes were reacted with 2 units (1:4000) of rabbit hemolysin (purchased from Shanghai Yuanye) at a 1:1 ratio and incubated in a 37°C water bath for 30 min to prepare 2x10 8 cell / mL sensitized sheep erythrocytes (EA) (antigen-antibody immune complex). In the reaction system, 95uL of normal human serum NHS (final concentration 2% v / v) / guinea pig serum GPS (final concentration 0.5% v / v) diluted in GVB++ buffer, purchased from Beijing Borsi) was used as a complement source. After adding 10uL of different concentrations (0.2nM–500nM) of the test sample / PBSE (10mM EDTA; positive control, set to 100% inhibition) / PBS (negative control, set to 0% inhibition), it was mixed with 95uL sensitized sheep erythrocytes (EA). At the same time, 95uL EA, 95uL water and 10uL PBS were mixed as a 100% hemolysis control. The mixture was incubated at 37°C for 0.5h, centrifuged at 2500xg for 10min, and 100uL of the supernatant was added to a 96-well plate to measure its absorbance at 412nm (A 412nm ). Thus, the amount of hemoglobin released during the lysis of red blood cells was quantified. The experiment was repeated three times independently, and the inhibition rate of the sample was calculated based on the hemolysis rate. Finally, the half-maximal inhibitory concentration (IC50) value of the test sample was obtained by four-parameter fitting. Inhibition rate % = 1-hemolysis rate % ((A 412nm Sample-A 412nm Positive) / (A 412nm Negative-A 412nm Positive))
[0299] Example 6: Alternative Complement Pathway Hemolysis Test (AH50)
[0300] The alternative pathway hemolysis inhibition assay (AH50) was similar to the CH50 assay and was performed according to the method described in CN1798841B. 2 mL of sterile rabbit defibrinated blood in Alsever's was washed three times with 20 mL of GVBMg-EGTA buffer (0.1% gelatin, 5 mM barbital, 145 mM NaCl, 2.5 mM MgCl2, 8 mM EGTA; pH 7.4). The precipitated red blood cells were diluted proportionally in GVBMg-EGTA buffer to prepare 2×10 8 cell / mL of rabbit red blood cells. In the reaction system, 95uL of normal human serum NHS (final concentration 43%) diluted in GVBMg-EGTA buffer was used as a complement source, and 10uL of different concentrations (0.6nM-1500nM) of the test sample / test sample / PBSE (10mM EDTA; positive control, set to 100% inhibition) / PBS (negative control, set to 0% inhibition) was added, and then mixed with 95uL RE. At the same time, water was used as a 100% hemolysis control, incubated at 37°C for 0.5h, centrifuged at 2500xg for 10min, 100uL of the supernatant was added to a 96-well plate, and its absorbance at 412nm was measured. The experiment was repeated three times independently, and the inhibition rate of the sample was calculated based on the hemolysis lysis rate. Finally, the half-maximal inhibition concentration (IC50) value of the test sample was obtained by four-parameter fitting. Inhibition rate % = 1-hemolysis rate % ((A 412nm Sample-A 412nm Positive) / (A 412nm Negative - A 412nm Positive))
[0301] Example 7: In vitro anti-complement classical / alternative pathway activity (CH50 / AH50) of OmCI recombinant protein, OmCI mutants and their modified derivatives
[0302] The in vitro activity of recombinant OmCI protein, cysteine-blocked OmCI mutants, and modified derivatives thereof (compounds described in Examples 1, 2, and 4) was evaluated using the methods of Examples 5 and 6. As shown in Table 3, the successfully expressed recombinant OmCI protein and its mutants all exhibited considerable in vitro complement hemolytic inhibitory activity, and fatty acid modification did not affect OmCI's complement inhibitory activity.
[0303] Table 3. In vitro hemolysis inhibition results of OmCI mutants and their derivatives against classical / alternative complement pathways
[0304] Example 8: Evaluation of Complement Hemolysis Inhibitory Activity (PNH50) Using PNH-like Erythrocytes
[0305] Inhibition of complement alternative pathway-mediated erythrocyte lysis was evaluated using an in vitro model of PNH-like erythrocytes. Normal human erythrocytes were sensitized with 2-aminoethylisothiourea bromide (AET) to inactivate cell surface complement regulatory proteins and induce a PNH-like phenotype as follows:
[0306] 2 mL of normal human erythrocytes were mixed with 2 mL of Aldrich's solution, washed three times with PBS, and centrifuged at 2500 x g, removing 10% of the upper layer of erythrocytes each time. 1 mL of washed erythrocytes was incubated with 4 mL of 8% w / v AET (pH 8.0) at 37°C for 10 minutes for sensitization, followed by three washes with PBS. The erythrocyte concentration in the erythrocyte stock solution was then adjusted with PBS so that the absorbance at 405 nm was 1.5-2.0 (indicating hemoglobin release) when 10 μL of the erythrocyte stock solution was diluted with 140 μL of water.
[0307] 1.5 mL of the above-mentioned erythrocyte stock solution was mixed with anti-CD55 antibody (BRIC216; Sigma-Aldrich, final concentration 6.7 μg / mL) and incubated on ice for 30 minutes. After washing once with PBS, the treated erythrocytes were resuspended in PBS-Mg (1 mM MgCl2 pH 6.4) to an initial volume of 1.5 mL. This erythrocyte preparation with an induced PNH phenotype was subjected to the following AP-mediated lysis assay.
[0308] Normal human serum was acidified to pH 6.4 with 0.2M HCl and supplemented with MgCl2 and EGTA to final concentrations of 2.5mM and 8mM, respectively. The reaction system was mixed with 60μL of normal serum NHS (final concentration approximately 53% v / v) and 10μL of PBS-Mg (set to 100% hemolysis as a negative control) / PBS-EDTA (10mM EDTA; 0% hemolysis as a positive control) / 10μL of sample at various concentrations (0.6nM-1500nM). The sample and serum were incubated on ice for 5 minutes, followed by the addition of 10μL of sensitized erythrocytes and 20μL of PBS-Mg buffer. The reaction was incubated at 37°C and 900rpm for 30 minutes, and then quenched by the addition of 50μL of ice-cold PBS containing 10mM EDTA. The remaining unlysed cells were centrifuged at 2500×g for 10 min, 100 μL of the supernatant was added to a 96-well plate, and the absorbance at 405 nm (A 405nm The amount of hemoglobin released during red blood cell lysis was quantified. The experiment was repeated three times independently, and the inhibition rate of the sample was calculated based on the hemolysis rate. Finally, the half-maximal inhibitory concentration (IC50) of the test sample was obtained by four-parameter fitting. 50 ) value. Inhibition rate % = 1-hemolysis rate % ((A 405nm Sample-A405nm Positive) / (A 405nm Negative - A 405nm Positive))
[0309] The recombinant OmCI protein (Example 1) and its modified derivatives, OmCIT90C-CM05 (Example 4.2) and OmCIT90C-CM14 (Example 4.5), were evaluated for complement inhibitory activity using PNH-like erythrocytes. As shown in Table 4, the successfully expressed recombinant OmCI protein and its modified derivatives exhibited considerable in vitro complement hemolytic activity.
[0310] Table 4. In vitro PNH-like erythrocyte hemolysis inhibition results of OmCI and its derivatives
[0311] Example 9. Molecular level study of receptor protein complement C5 binding
[0312] Surface plasmon resonance (SPR) was used to determine the affinity of recombinant OmCI protein (Example 1), mutant OmCIT90C (Example 2), and modified OmCI derivatives OmCIT90C-CM05 (Example 4.2) and OmCIT90C-CM14 (Example 4.5) for the C5 receptor. Real-time affinity measurements were performed on a Biacore 8000 system at 25°C using PBST-0.02 buffer as the running buffer and a blank control. Test samples were serially diluted in the running buffer from 300 nM to 3 nM. The receptor protein (human complement C5 protein) was diluted to a concentration of 10 μg / mL in 10 mM sodium acetate (pH 5.0). Human complement C5 protein was immobilized on a CM5 sensor chip using amino coupling in PBS buffer at a continuous flow rate of 10 μL / min for 200 s. The ligand density was approximately 1900-2400 resonance units (RU). The experiment was performed using different concentrations of the test sample dilutions and a blank control in PBST-0.02 running buffer. The flow rate was 30 μL / min, with an association time of 60 s and a dissociation time of 200 s. Real-time data were collected using BiaControl Software 2.0. A 2 M MgCl2 solution was used for regeneration at a flow rate of 30 μL / min for 30 s to disrupt the strong electrostatic interaction between the OmCI protein and C5.
[0313] The data were corrected for the average baseline determined by three buffer injections and the corresponding signal measured in the online blank channel was subtracted. The data were fitted to a Langmuir 1:1 binding model for bimolecular complex formation and kinetic parameters were determined using BiaEvaluation Software 2.0. The results are listed in Table 5 and show that OmCI and its mutants and fatty acid-modified derivatives have comparable in vitro affinities for human complement C5 protein. Mutations or modifications do not affect the binding ability of OmCI to the C5 receptor.
[0314] Table 5. Affinity of OmCI and its mutants and modified derivatives for complement C5 in vitro
[0315] Example 10. Molecular level albumin binding studies
[0316] Surface plasmon resonance (SPR) was used to determine the affinity of recombinant OmCI protein (Example 1), mutant OmCIT90C (Example 2), and modified OmCI derivatives OmCIT90C-CM05 (Example 4.2) and OmCIT90C-CM14 (Example 4.5) for human serum albumin (HSA). Real-time affinity measurements were performed on a Biacore 8000 system (GE Healthcare) at 25°C. The samples were serially diluted in 0.02% PBST as the running buffer and a blank control, with concentrations ranging from 3000 nM to 40 nM. HSA was diluted to a concentration of 10 μg / mL in 10 mM sodium acetate (pH 4.5). HSA was immobilized on a CM5 sensor chip using amino coupling in PBS at a continuous flow rate of 10 μL / min for 200 s. The ligand density was approximately 3500 resonance units (RU). The experiment was conducted using different concentrations of the test sample dilutions and a blank control in the running buffer, flowing sequentially through the control channel and the experimental channel at a flow rate of 30 μL / min, with an association time of 60 seconds and a dissociation time of 200 seconds. Real-time data signals were collected using BiaControl Software 2.0. Regeneration was performed using 10 mM Gly-HCl solution (pH 2.5) at a flow rate of 30 μL / min for 30 seconds to disrupt the strong electrostatic interactions between fatty acids and albumin.
[0317] The data were corrected for the average baseline determined by three buffer injections and the corresponding signal measured in the online blank channel was subtracted. The data were fitted to a Langmuir 1:1 binding model for bimolecular complex formation and the kinetic parameters were determined using BiaEvaluation Software 2.0. The results are listed in Table 6 and show that OmCI and its mutants do not bind to human serum albumin (HSA), while acylated OmCI proteins can bind to HSA via the conjugated fatty acid.
[0318] Table 6. Affinity of OmCI and its mutants and modified derivatives for human serum albumin (HSA)
[0319] Example 11. Pharmacokinetic studies
[0320] Female C57BL / 6J mice, 6-8 weeks old, were housed under standard conditions. Mice (approximately 20 g) were divided into three groups and administered a single subcutaneous dose of OmCI (15 mg / kg), OmCI-T90C-CM05 (15 mg / kg), or OmCIT90C-CM14 (15 mg / kg) in PBS via subcutaneous injection into the neck. Blood samples were collected via the tail vein at 0.1, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours after administration (three animals per group at each time point). Blood was drawn into EDTA-2K-coated tubes, placed on ice, and centrifuged at 1200 × g for 10 minutes at 4°C. Plasma was then transferred to Micronic tubes and stored at -20°C. The concentration of the target protein in plasma was determined by sandwich ELISA.
[0321] A transparent 96-well plate was supplemented with 50 μL of human complement C5 protein (purchased from Complement Technology) dissolved in PBS at 10 μg / mL and coated overnight at 4 ° C. After washing 3 times with PBS containing 0.05% v / v Tween 20 (PBST-0.05), it was blocked with 200 μL Blocker Casein (purchased from Thermo Fisher Scientific) at room temperature for 1 hour and washed again. The plasma sample was diluted in PBS at 1:5 to a constant content of up to 20% v / v mouse plasma in the sample matrix and incubated at 37 ° C for 1 hour. After washing, 50 μL of rabbit polyclonal antibody against OmCI diluted to 5 μg / mL using blocking solution (obtained by Anhui Global Gene Technology through immune stimulation) was added for 1 hour. After washing, 50uL of 1:4000 blocking solution diluted HPR-goat anti-rabbit IgG (AB205718; purchased from Abcam) was added and incubated for 1h, and 100μL TMB (purchased from Thermo Fisher Scientific) was added to each well for color development. After 15 minutes, 2M sulfuric acid was added to terminate the reaction and the absorbance was measured at 450nm. A separate standard curve was constructed to determine the plasma level of each protein. The standard curve was obtained by a dilution series of purified recombinant OmCI protein with a determined concentration in PBS, and was also supplemented with up to 20% v / v mouse plasma from untreated animals. The plasma concentration (μg / mL) of each sample was calculated using the parameters derived from the standard curve (log-log regression analysis). Pharmacokinetic parameters were calculated using a two-compartment model and drug statistical software (DAS, version 2.0; Chinese Mathematical Pharmacology Committee). The results are listed in Table 7.
[0322] Table 7. Pharmacokinetic parameters of OmCI mutants and their derivatives in mice
[0323] Abbreviations: t1 / 2α distribution half-life; t1 / 2β elimination half-life; Cmax: maximum plasma concentration; CL: clearance; AUC: area under the curve;
[0324] The sequences used in this article are as follows:
[0325] SEQ ID NO: 1
[0326] >Natural OmCI
[0327] SEQ ID NO:2
[0328] >OmCI protein with periplasmic binding protein and enterokinase recognition site fused to its N-terminus
[0329] SEQ ID NO:3
[0330] >OmCI mutant containing an N-terminal 6-histidine (His6) tag and a ubiquitin-like modifier (SUMO) tag (His6-SUMO-OmCIT90C)
[0331] SEQ ID NO:4
[0332] >OmCI mutant T90C (OmCIT90C)
[0333] SEQ ID NO:5
[0334] >OmCI mutant K95C (OmCIK95C)
[0335] SEQ ID NO:6
[0336] >OmCI mutant T97C (OmCIT97C)
[0337] SEQ ID NO:7
[0338] >OmCI mutant E126C (OmCIE126C)
[0339] SEQ ID NO:8
[0340] >OmCI mutant S156C (OmCIS156C)
[0341] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A modified protein, comprising a protein portion and a modification portion, wherein a cysteine residue is introduced into the protein portion by mutation, and the modification portion is connected to the protein portion via the cysteine residue introduced into the protein portion, wherein the protein is OmCI or an active fragment thereof.
2. An OmCI mutant having the amino acid sequence shown in SEQ ID NO: 1, wherein T90, K95, T97, E126 or S156 is mutated to a cysteine residue.
3. A pharmaceutical composition comprising the modified protein according to claim 1 or the OmCI mutant according to claim 2 and a pharmaceutically acceptable excipient.
4. Use of the modified protein according to claim 1 or the OmCI mutant according to claim 2 in the preparation of a drug.
5. An albumin binder, the structure of which is shown in the following formula: [R1-(X1) m -(X2) n -K] o -X3-(ε-R2); In the formula, K is lysine R1 is substituted or unsubstituted C 1-20 acyl group; m is an integer from 0 to 5; n is an integer from 0 to 5; o is an integer of 1-3 (preferably 1 or 2); X1 and X2 are independently selected from the following group: alanine (Ala), D-alanine (D-Ala), β-alanine (β-Ala), 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), glutamic acid (Glu), D-glutamic acid (D-Glu), γ-glutamic acid (γ-Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met), tranexamic acid (Trx), 8-amino-3,6-dioxaoctanoic acid (AEEA), PEG; X3 does not exist or is a connecting part as shown below: (R3) o R4R5; wherein R3 is substituted or unsubstituted C 1-3 Acyl, R4 is C 5-8 Aryl or heteroaryl, R5 is substituted or unsubstituted amino; R2 is selected from halogen-substituted C 1-6 Acyl.
6. An isolated nucleic acid molecule encoding the OmCI mutant of claim 2.
7. An expression vector comprising the isolated nucleic acid molecule of claim 6.
8. A host cell, comprising the expression vector of claim 7 or the nucleic acid molecule of claim 6 integrated into the genome of the host cell.
9. Use of the OmCI mutant according to claim 2 in preparing the modified protein according to claim 1.
10. A method of treatment, comprising the step of administering a therapeutically effective amount of the modified protein of claim 1, the OmCI mutant of claim 2, or the pharmaceutical composition of claim 3 to a subject in need thereof.
Citation Information
Patent Citations
Modified omci as complement inhibitor
CN102341407A
Growth hormones with prolonged in-vivo efficacy
CN103002918A
Complement inhibitors from ticks
CN1798841A
